Skip to main content

Table 1 Comparison of the baseline characteristics of the patients in the PCD and POBA groups and the 1, 2 and 5 years mortality rates

From: Paclitaxel and mortality in patients with claudication and de novo femoropopliteal lesions: a historical cohort study

 

POBA (n = 380)

PCD (n = 320)

p-value

Age

67.7y + −8.8

68.5y + − 8.2

p = 0.14

Female

27.1% (n = 103)

27.8% (n = 89)

p = 0.835

Active Tobacco Use

23.4% n = (89)

14.7% (n = 47)

p = 0.004

Cancer

10.5% n = (40)

10.3% (n = 33)

p = 0.93

Creatinin

92.8 + −81.0

88.7 + −68.7

p = 0.57

Renal Insufficiency

8.4% (n = 32)

7.5% (n = 24)

p = 0.65

Diabetes melllitus

31.1% n = (118)

23.1% (n = (74)

p = 0.019

Hyperlipidemia

59.2% n = (225)

39.1% (n = 125)

p < 0.001

Hypertension

58.9% n = (224)

42.2% (n = 135)

p < 0.001

Heart failure

2.9% n = (11)

1.3% (n = 4)

p = 0.13

Coronary Artery Disease

44.2% n = (168)

34.3% (n = 97)

p < 0.001

COPD

15% n = (57)

9.4% (n = 30)

p = 0.03

Charlson Score

0.44 ± 0.98

0.31 ± 0.9

p = 0.04

1 year mortality rate

4.6%

1.6%

p = 0.03

2 year mortality rate

7.5%

6.2%

p = 0.53

5 year mortality rate

19.4%

16.6%

p = 0.49